Abstract
Type 1 diabetes (T1D) is an organ-specific autoimmune disease resulting from the specific destruction of insulin-producing pancreatic β-cells, culminating in a state of hypoinsulinemia and hyperglycemia. Pathogenesis of T1D comprises complex series of events from the initial sensitization of antigen-presenting cells (APCs) to β-cell antigens to almost total insulin deficiency due to islet destruction. Although it is established that the interaction of environmental factors with genetic traits plays a pivotal role in the pathogenesis of T1D, in most cases, the exact trigger of anti-islet autoimmunity and how genetic and environmental factors regulate its progression, ultimately leading to the development of T1D remain elusive. In this review, based on the recent advances in understanding the role of innate immunity in development of autoimmune diseases, we focus on the possibility that aberrant regulation of the innate immune system frequently observed in animal models and patients with T1D, induces T1D by triggering anti-islet autoimmunity in the context of the autoimmuneprone environment; this information might provide an insight into possibilities for therapeutic intervention modulating innate immunity to mitigate or prevent T1D.
Keywords: Innate immunity, β-cell death, macrophages, dendritic cells, NK cells, NK T cells, γδ T cells, TLRs
Current Molecular Medicine
Title: Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Volume: 9 Issue: 1
Author(s): Hun Sik Kim and Myung-Shik Lee
Affiliation:
Keywords: Innate immunity, β-cell death, macrophages, dendritic cells, NK cells, NK T cells, γδ T cells, TLRs
Abstract: Type 1 diabetes (T1D) is an organ-specific autoimmune disease resulting from the specific destruction of insulin-producing pancreatic β-cells, culminating in a state of hypoinsulinemia and hyperglycemia. Pathogenesis of T1D comprises complex series of events from the initial sensitization of antigen-presenting cells (APCs) to β-cell antigens to almost total insulin deficiency due to islet destruction. Although it is established that the interaction of environmental factors with genetic traits plays a pivotal role in the pathogenesis of T1D, in most cases, the exact trigger of anti-islet autoimmunity and how genetic and environmental factors regulate its progression, ultimately leading to the development of T1D remain elusive. In this review, based on the recent advances in understanding the role of innate immunity in development of autoimmune diseases, we focus on the possibility that aberrant regulation of the innate immune system frequently observed in animal models and patients with T1D, induces T1D by triggering anti-islet autoimmunity in the context of the autoimmuneprone environment; this information might provide an insight into possibilities for therapeutic intervention modulating innate immunity to mitigate or prevent T1D.
Export Options
About this article
Cite this article as:
Kim Sik Hun and Lee Myung-Shik, Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes, Current Molecular Medicine 2009; 9 (1) . https://dx.doi.org/10.2174/156652409787314471
DOI https://dx.doi.org/10.2174/156652409787314471 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Chemokines and Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued) Paracoccidioides spp. and Histoplasma capsulatum: Current and New Perspectives for Diagnosis and Treatment
Current Topics in Medicinal Chemistry Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets